Summary of FDA-approved CAR-T cell product manufacturing
| Product name . | Commercial name . | Cell population prior to T-cell activation . | Starting leukopak storage . | Transgene integration method . | Final product storage . | References . |
|---|---|---|---|---|---|---|
| Tisa-cel | Kymriah | Enriched T cells | Frozen | Lentivirus | Frozen | Fowler et al. (2022), Maude et al. (2018), Schuster et al. (2019), Tyagarajan et al. (2019) |
| Axi-cel | Yescarta | PBMCs (from Ficoll gradient enrichment) | Fresh | Retrovirus | Frozen | Jacobson et al. (2022), Locke et al. (2022), Roberts et al. (2018) |
| Brexu-cel | Tecartus | CD19-depleted and CD4/CD8-enriched T cells | Fresh | Retrovirus | Frozen | Mian and Hill (2021), Wang et al. (2020) |
| Liso-cel | Breyanzi | CD4 and CD8 T cells separately | Not reported | Lentivirus | Frozen | Kamdar et al. (2022), Sehgal et al. (2022), Teoh and Brown (2022) |
| Idecabtagene vicleucel | Abecma | PBMCs | Not reported | Lentivirus | Frozen | Al Hadidi et al. (2023), Hansen et al. (2023), Raje et al. (2019) |
| Ciltacabtagene autoleucel | Carvykti | Enriched T cells | Frozen | Lentivirus | Frozen | Berdeja et al. (2021); Committee for Medicinal Products for Human Use (2022); San-Miguel et al. (2023) |
| Product name . | Commercial name . | Cell population prior to T-cell activation . | Starting leukopak storage . | Transgene integration method . | Final product storage . | References . |
|---|---|---|---|---|---|---|
| Tisa-cel | Kymriah | Enriched T cells | Frozen | Lentivirus | Frozen | Fowler et al. (2022), Maude et al. (2018), Schuster et al. (2019), Tyagarajan et al. (2019) |
| Axi-cel | Yescarta | PBMCs (from Ficoll gradient enrichment) | Fresh | Retrovirus | Frozen | Jacobson et al. (2022), Locke et al. (2022), Roberts et al. (2018) |
| Brexu-cel | Tecartus | CD19-depleted and CD4/CD8-enriched T cells | Fresh | Retrovirus | Frozen | Mian and Hill (2021), Wang et al. (2020) |
| Liso-cel | Breyanzi | CD4 and CD8 T cells separately | Not reported | Lentivirus | Frozen | Kamdar et al. (2022), Sehgal et al. (2022), Teoh and Brown (2022) |
| Idecabtagene vicleucel | Abecma | PBMCs | Not reported | Lentivirus | Frozen | Al Hadidi et al. (2023), Hansen et al. (2023), Raje et al. (2019) |
| Ciltacabtagene autoleucel | Carvykti | Enriched T cells | Frozen | Lentivirus | Frozen | Berdeja et al. (2021); Committee for Medicinal Products for Human Use (2022); San-Miguel et al. (2023) |